Extract Cimicifuga racemosa by an Isopropanolic in vivo Tumors Lack of Promotion of Estrogen-dependent Mammary Gland

Abstract

Cimicifuga racemosa (CR) is widely used in the treatment of menopausal symptoms. Mechanistic studies suggest that unlike hormone-replacement therapy, CR does not stimulate estrogen-receptor positive breast cancer cells. To evaluate CR safety, we performed an in vivo investigation of a clinically tested isopropanolic CR extract. Mammary tumors were induced… (More)

4 Figures and Tables

Topics

  • Presentations referencing similar topics